Helixgate

Helixgate

Uncategorized

Opinion: Even in abortion-protecting states, teens face unnecessary barriers to care

On May 28 the Nevada Supreme Court made the unanimous decision of halting enforcement of the state’s abortion parental notification law, allowing teens to access abortion services without being mandated to inform their caregivers. The ruling comes in response to a case filed by a Nevada physician and Planned Parenthood against a 1985 parental notification law that had been blocked under Roe v. Wade and was first enforced beginning in July 2025.

While the state Supreme Court’s decision grants only a preliminary injunction while the case proceeds through the lower courts, it marks a momentous step in addressing the current barriers to abortion access for teens even in abortion-protective states.

Read the rest…

Read More

Published

on

On May 28 the Nevada Supreme Court made the unanimous decision of halting enforcement of the state’s abortion parental notification law, allowing teens to access abortion services without being mandated to inform their caregivers. The ruling comes in response to a case filed by a Nevada physician and Planned Parenthood against a 1985 parental notification law that had been blocked under Roe v. Wade and was first enforced beginning in July 2025.

While the state Supreme Court’s decision grants only a preliminary injunction while the case proceeds through the lower courts, it marks a momentous step in addressing the current barriers to abortion access for teens even in abortion-protective states.

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Read More

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Read More

Continue Reading

Uncategorized

RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.

But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.

Read the rest…

Read More

Published

on

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.

But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.

Read the rest…

Read More

Continue Reading

Uncategorized

Nonprofit buys experimental cancer drug to maintain patient access

In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.

As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.

Read the rest…

Read More

Published

on

In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.

As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.

Read the rest…

Read More

Continue Reading
Advertisement

Trending